Full Press Release Details
WASHINGTON, May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL and online from May 6-9, 2023.
The following will be presented:
Presentation Title: "THE ROLE OF TENASCIN-X IN IDIOPATHIC GASTROPARESIS: WGS ANALYSIS"
Poster Number: Su1618
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
Presentation Title: "POOLED EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS STUDY VP-VLY-686-3301 AND VP-VLY-686-2301"
Poster Number: Su1632
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
Presentation Title: "EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301"
Poster Number: Su1633
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
Presentation Title: "A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS"
Poster Number: Su1634
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
For more information on DDW 2023, please refer to https://ddw.org/.
About Vanda Pharmaceuticals Inc.
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.